FDA User Fee Reauthorization Clears Hurdle In Senate With Bipartisan Support image

Health Affairs Blog, May 15, 2017
Rachel Sachs (Academic Fellow Alumna)


Read the full article

From the article:

On Thursday, May 11, the Senate Committee on Health, Education, Labor and Pensions marked up the proposed Food and Drug Administration (FDA) user fee reauthorization bill and voted 21-2 to advance it to the full Senate. The bill would reauthorize the fee system for the FDA’s approval of drugs, medical devices, generic drugs, and biosimilars. Recognizing both the must-pass nature of the bill and the partisan climate in Congress right now, the committee and its staff smartly managed to keep the bill fairly clean, adding few non-funding related provisions relative to some past user fee agreements (UFAs). Still, the full text clocks in at just under 200 pages, including amendments.

Read more here!

biotechnology fda health care finance health law policy pharmaceuticals rachel sachs